The risk of conduction system abnormalities (CSA) after transcatheter aortic valve implantation remains high. We aimed to evaluate the impact of mitral annular calcium (MAC) score on the development of CSA after transcatheter aortic valve implantation.
T
ranscatheter aortic valve implantation (TAVI) is considered as the standard of care for intermediate-to-high operative risk patients with severe aortic stenosis. 1 However, one of the most frequent and deleterious post-TAVI complications appears to be new conduction system abnormalities (CSA). Approximately one-quarter to half of patients undergoing TAVI may experience clinically significant CSA resulting in prolongation of hospital stay or even permanent pacemaker implantation. [2] [3] [4] The clinical predictors of TAVI-related CSA have been described in detail in comprehensive meta-analyses. 5, 6 However, whether anatomic factors, such as aortic or mitral valve Ca++ distribution patterns, predict CSA is still controversial. Several recent reports suggested that the left aortic valve (AoV) cusp Ca++, membranous septum length, and left ventricular outflow tract (LVOT) Ca++ might serve as predictors for post-TAVI pacemaker implantation. [7] [8] [9] Mitral annular calcium (MAC) was documented as prevalent in patients with severe AS, as well as a marker of adverse post-TAVI outcomes. [10] [11] [12] The anatomic proximity of the mitral annulus, especially its anterior part, to the AV node, suggests a causative effect for post-TAVI CSA. 13 We assumed that the MAC score could quantitate the degenerative changes in the mitral annulus and aortomitral continuity and serve as a marker of the degeneration of the conduction system. Thus, the aim of the study was to evaluate the impact of MAC to development of new CSA in patients without preexisting CSA undergoing TAVI.
METHODS

Study Population
A prospectively maintained database, including 445 consecutive patients with severe symptomatic AS who underwent TAVI procedure at a single tertiary center between 2012 and 2015, was analyzed. Exclusion criteria were the presence of permanent pacemaker (n=42), implantable cardioverter-defibrillator (n=4), complete left bundle branch block (CLBBB; n=39), complete right bundle branch block (CRBBB; n=36), left anterior hemiblock (n=65), left posterior hemiblock (n=5), first-degree AV block (n=56), second-degree AV block (n=3), or QRS segment ≥120 ms (n=4), as well as prior valve replacement or repair: aortic (n=13), mitral (n=9), or tricuspid (n=1). The patients with incomplete left bundle branch block or right bundle branch block (QRS segment, <120 ms; n=14) were included. The study cohort included 168 patients. Baseline clinical data, risk factors, and comorbidities were retrieved from the electronic medical records. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. The study was approved by the institutional review board, and all participants gave written informed consent.
Study Clinical End Point
The primary end point was determined as the occurrence of any new CSA (combination of transient or persistent CLBBB or transient or persistent high-degree AV block) during the post-TAVI procedure hospitalization.
Computed Tomographic Acquisition Protocol and Data Analysis
The routine pre-TAVI evaluation includes an ECG-gated noncontrast computed tomography (CT) followed by a contrastenhanced scan. Scans were performed utilizing a 256-slice scanner (Brilliance iCT; Philips Healthcare, Cleveland, OH). The Ca++ core scan was acquired in the craniocaudal direction starting at the carina and ending at the diaphragm. Technical parameters: collimation, 112×0.625 mm; voltage, 120 kV; amperage, 377 mA; and slice thickness, 2 mm. The contrast-enhanced CT scan was craniocaudal with a collimation of 96×0.625 mm, a gantry rotation time of 330 ms, tube current of 400 to 600 mA at 100 to 120 kV, and pitch value of 0.2. Intravenous injection of 70 to 85 mL of nonionic contrast agent (Iomeron 350; Bracco, Milan, Italy) at a flow rate of 3.5 mL/s was followed by a 30-mL saline chase bolus (5 mL/s). Automated peak enhancement detection in the descending aorta was used for timing of the scan, and the data acquisition was automatically initiated at a threshold level of 100 Hounsfield units. Acquisition was performed during an inspiratory breath-hold while the ECG was recorded simultaneously to allow retrospective gating of the data. All images were reconstructed with a slice thickness of 0.67 mm and a slice increment of 0.34 mm. CT datasets were transmitted to a dedicated postprocessing platform (IntelliSpace Portal, version 7 V; Philips).
Ca++ Score Analysis
Ca++ score quantification was performed using the noncontrast ECG-gated chest CT scan with a dedicated software (Heartbeat CS, IntelliSpace Portal, version 7 V; Philips) implementing the Agatston method. [14] [15] [16] Briefly, lesion-specific scores were calculated as the product of the area of each calcified focus and peak CT Hounsfield unit value. A grading scale of 1 to 4 was used according to the following: grade 1, 130 to 199 HU; grade 2, 200 to 299 HU; grade 3, 300 to 399 HU; and grade 4, ≥400 HU. Grades were summed across all lesions identified within AoV and mitral annulus to provide
CLINICAL PERSPECTIVE
This study demonstrates that high mitral annular calcium score is a powerful predictor for the posttranscatheter aortic valve implantation new left bundle branch block or high-degree atrioventricular block in patients without preexisting conduction system abnormalities. Therefore, a high index of suspicion for conduction system abnormalities and close postprocedural monitoring in patients with high mitral annular calcium scores is strongly advised. Routine incorporation of mitral annular calcium score assessment should become an integral part of the pretranscatheter aortic valve implantation evaluation.
AoV and mitral annulus Ca++ scores. Ca++ score was separately performed by 3 experienced cardioradiologists (Y.B., D.S., and M.D.S.) who were blinded to the patient's clinical data. Noncontrast and contrast-enhanced axial images were paired at the same anatomic level to accurately identify the aortic cusps, aortic sinuses, and the mitral valve annulus. The presence of LVOT Ca++ was determined by the contrast CT scan using axial, coronal, and sagittal planes and was defined as any calcification below the level of the AoV annulus plane within 8 mm (ie, within 4 slices of 2-mm noncontrast scan). Thus, LVOT Ca++ was scored by noncontrast axial scan separately from AoV Ca++ and MAC. Calcifications attributed to coronary arteries, mitral leaflets, and subvalvular apparatus (papillary muscles or chordae), as well as intramyocardial Ca++, were differentiated from MAC, AoV, or LVOT Ca++ and were not scored.
TAVI Procedure
Balloon predilatation of the AoV was performed in 72% of patients. Medtronic CoreValve, Medtronic Engager, and Medtronic Evolut valves were implanted in 61, 6, and 5 patients, respectively. Edwards SAPIEN, SAPIEN 3, and SAPIEN XT valves were implanted in 87, 8, and 1 patients, respectively. Femoral, apical, axillar, and transaortic accesses were used in 107, 48, 11, and 2 patients, respectively. Valve sizes of 23, 26, 29, and 31 were used and were based on the CT-measured perimeter of the aortic annulus, per vendor recommendations. Balloon postdilatation was performed in 21% of patients, with significant aortic paravalvular leak as the leading indication.
Statistical Analysis
Continuous variables were evaluated for their normal distribution using a histogram and were expressed as mean±SD, if they were normally distributed, or as median and interquartile range if the distribution was not normal. Independent samples t test or Mann-Whitney U test were used to compare continuous variables between patients with and without the primary end point. The χ 2 test or Fisher exact test were used for categorical variable comparison between the patients who developed primary end point and others. Incidence of primary end point was compared by the different quartiles of MAC score and between those with MAC above or below the median using χ 2 test. Multivariable logistic regressions were performed to evaluate the predictive value of different parameters for development of new post-TAVI CSA. Age, female sex, as well as the variables with P <0.25 in univariate analysis were applied for multivariable logistic regression analysis. At the multivariable analysis, the AoV, MAC, and LVOT Ca++ scores were included as continuous variables, and in further analysis, they were included as categorical variables using the median value and the quartiles as the cutoff values. Odds ratio (OR) and 95% CIs were reported. All statistical tests were 2 tailed. P <0.05 was considered as statistically significant. Statistical analysis was performed with a statistical software package (IBM Corp, released 2016; IBM SPSS Statistics for Windows, version 24.0; IBM Corp, Armonk, NY).
RESULTS
Clinical Characteristics of Entire Cohort
Mean age was 80±7 years; 51% were women. Diabetes mellitus, chronic renal failure, prior myocardial infarction, coronary artery bypass grafts, and baseline atrial fibrillation were present in 42%, 21%, 18%, 14%, and 29% of patients, respectively. Mean values of preprocedural PR interval and QRS segment were measured as167±24 and 96±13 ms, respectively. Median values and interquartile range of MAC and AoV Table 1 . By univariate analysis, patients with new CSA were documented to have significantly higher mean MAC scores, larger implanted valve sizes, and higher body mass index (BMI; Table 1 ).
Conduction System Abnormalities
A total of 87 new CSAs were documented in 81 patients. High-degree AV block, CLBBB, or both in were documented in 26, 61, and 6 patients, respectively. Transient high-degree AV block and transient CLBBB were documented in 2 and 24 patients, respectively. Persistent high-degree AV block, persistent CLBBB, or both were documented in 24, 37, and 6 patients, respectively. Alternating CLBBB/CRBBB was documented in 1 patient. New isolated first-degree AV block and CRBBB were documented in 9 and 5 patients, respectively. Permanent pacemakers were implanted in 29 patients (17% of the entire cohort), during hospitalization. Indications for pacemaker insertion included persistent high-degree AV block (n=24), transient high-degree AV block (n=1), CLBBB with slow atrial fibrillation (n=2), new CLBBB with severe PR interval prolongation (>400 ms; n=1), and alternate CLBBB/CRBBB (n=1). Pacemakers were not implanted in patients with transient CLBBB (n=26) and persistent CLBBB (n=27).
Direct correlation between higher MAC score and the incidence of the primary end point was documented (P=0.03; Figure 3 ). CSAs were more prevalent in the presence of higher MAC scores: one-third in the first quartile of MAC score (MAC score, <140) and two-thirds of the patients in the fourth quartile of MAC score (MAC score, >2700). The clinical examples are presented in Figure 4 . The incidence of the primary end point in patients with above median MAC score (658) was observed in 60% compared with 40% in patients with MAC scores below the median, P=0.009.
The multivariable analyses of the different predictors of the primary end point are shown in Tables 2 through  4 
DISCUSSION
The current study sought to understand the impact of MAC score on the presence of new clinically significant CSA in post-TAVI patients. To the best of our knowledge, this is the first study to demonstrate a strong correlation between quantitative MAC scores by quartiles and the occurrence of new post-TAVI CSA. Our cohort specifically addressed selected patients without preexisting CSA and thus was able to identify the MAC score as an independent predictor of new left bundle branch block or high-degree AV block. Clinically meaningful cutoff values using median MAC score and MAC quartiles demonstrated both the median MAC score and the third and fourth MAC quartiles as independent predictors for post-TAVI CSA. Moreover, the fourth quartile of MAC score was shown to be the most powerful predictor for CSA. These findings might warrant different clinical approaches with closer monitoring and a higher index of suspicion for CSA in these patients. Thus, we suggest that the patients with high MAC score should be monitored in intensive cardiac unit for a longer time and accurately followed up after discharge, including serial ECG and Holter monitoring for several weeks after procedure. However, more long-term follow-up is needed to confirm this suggestion.
The correlation between MAC severity and distribution and CSA was documented in an early echocardiographic study. 17 Pacemaker implantation was reported as prevalent in elderly patients with MAC and calcific aortic stenosis. 18 After surgical AoV replacement, MAC was recorded as a predictor of poor outcome and pacemaker implantation. 19 Ca++ deposits close to implantation area, either in the AoV or in the LVOT, were the main focus of previous studies. Only a few papers assessed the influence of MAC itself. 12, 20, 21 The presence of Ca++ in the mitral annulus, assessed visually by echocardiography, along with CRBBB, was documented as independent predictor of post-TAVI permanent pacemaker implantation. 20 Severe MAC assessed visually by CT was reported as a strong predictor for all-cause mortality and post-TAVI permanent pacemaker implantation. 12 However, at variance with the current study, patients with preexisting CSA and permanent pacemakers were not excluded in the aforementioned studies. 12, 20 Recently, severe circumferential MAC evaluated visually by CT was found to be an independent predictor of cardiovascular mortality on longterm follow-up. 21 In discordance with our findings, the left coronary cusp Ca++ was previously identified as a predictor of permanent pacemaker implantation. 7 This discrepancy could be attributed to different Ca++ quantitation methods and different postprocessing platforms. Moreover, patients with preexisting CSA were not excluded, and MAC was not addressed in the aforementioned study. 7 Shorter interventricular septum length was documented as a predictor for post-TAVI pacemaker implantation. 8 This study addressed the anatomic proximity of the conduction system to the location of intraprocedural balloon inflation. In addition, basal septum Ca++ (which was not quantified) was identified as a predictor for pacemaker implantation. The presence of Ca++ in the AoV or LVOT did not predict CSA in our study.
Increased BMI was found to be an independent CSA predictor in the current study. A strong association between increased BMI and MAC was documented previously in studies utilizing cardiac CT or echocardiography. 22, 23 One could speculate that increased BMI acting as a proinflammatory state by itself may result in accelerated mitral annular Ca++ deposition. 24 Thus, the correlation demonstrated between CSA and increased BMI might be indirect. Larger valve size was also found to be an independent predictor of CSA. This is in accordance with reported data. 20 No correlation was found between atrial fibrillation and CSA in the current study. A recent analysis from the PARTNER trial documented only new-onset periprocedural atrial fibrillation to be a predictor for post-TAVI CSA. 25 However, persistent atrial fibrillation was not found to be correlated to CSA. 25 The current analysis included only patients with persistent atrial fibrillation and is in agreement with the PARTNER and other studies on this issue. 20 The strong correlation between high MAC score and new CSA after TAVI could be attributed to several mechanisms. Elevated MAC score may serve as a general indicator of the extent and severity of degenerative changes in the close anatomic proximity to the conduction system. Thus, one could speculate that MAC might serve as a marker of occult CSA undetected by a standard ECG, which is manifested after TAVI. In addition, repeated procedural balloon inflations abutting the stiff calcified mitral annulus, especially its anterior part, could result in balloon displacement and direct damage to the adjacent conduction system. Further investigation is needed to elucidate the pathophysiology of mitral degenerative changes.
Limitations
This is a retrospective single-center study with its related inherent limitations. No long-term follow-up was available. Therefore, no conclusions can be drawn on the long-term effects of MAC scores on patients with persistent versus transient CLBBB, in whom no pacemaker was implantation was performed. Because of the noncontrast nature of Ca++ score analysis, Ca++ quantification was not available for each aortic cusp, the anterior and posterior mitral leaflets, the anterior and posterior parts of mitral annulus, and LVOT. However, aligning the same anatomic level of the contrast and noncontrast images enabled accurate discrimi- nation between Ca++, related to AoV, mitral annulus, LVOT, coronary arteries, mitral valve chordae, and pericardium. MAC quantitation was performed using 2-mm slice thickness at variance with from the original method described by Agatston et al, 14 for coronary arteries. However, it has been demonstrated that the clinical relevance of coronary calcification remains regardless of the slice thickness or other modifications of the original Agatston. We believe, therefore, that the modification to the original Agatston by using 2-mm slice thickness for MAC measuring might be accurate enough for the quantification of the voluminous calcification that characterize MAC. The current analysis used the MAC score quartiles rather than the MAC numeric value to minimize the differences between the 2 methods and to enables application of our findings to studies performed with different scanners or methods. But head-to-head comparison between the 2 methods for MAC measuring is warranted. In addition, utilization of different slice thicknesses ranging from 2 to 3 mm for quantitation of valvular and coronary calcium has been reported using different CT scanners or protocols. 22, 26, 27 
Conclusions
This study documented MAC score to be an independent predictor for post-TAVI CSA. Patients with high MAC score category (fourth MAC score quartile) should be considered at high risk for CSA, warranting closer monitoring. Thus, routine incorporation of MAC score assessment should be considered in the pre-TAVI evaluation. 
